About sionna therapeutics inc - SION
Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.
SION At a Glance
Sionna Therapeutics, Inc.
21 Hickory Drive
Waltham, Massachusetts 02451
| Phone | 1-617-819-2020 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -61,688,000.00 | |
| Sector | Health Technology | Employees | 41 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
SION Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
SION Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,504,585.366 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SION Liquidity
| Current Ratio | 14.491 |
| Quick Ratio | 14.491 |
| Cash Ratio | 14.159 |
SION Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -51.905 |
| Return on Equity | -61.438 |
| Return on Total Capital | -34.97 |
| Return on Invested Capital | -56.274 |
SION Capital Structure
| Total Debt to Total Equity | 5.85 |
| Total Debt to Total Capital | 5.527 |
| Total Debt to Total Assets | 5.248 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 4.919 |